daunorubicin has been researched along with wp 744 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aggarwal, BB; Ashikawa, K; Fokt, I; Priebe, W; Shishodia, S | 1 |
Baer, MR; Bernacki, RJ; Brooks, TA; Bundy, BN; Ford, LA; Minderman, H; O'Loughlin, KL; Priebe, W; Vredenburg, MR | 1 |
2 other study(ies) available for daunorubicin and wp 744
Article | Year |
---|---|
Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; DNA, Neoplasm; Doxorubicin; Humans; I-kappa B Proteins; Jurkat Cells; NF-kappa B; NF-KappaB Inhibitor alpha; Transcription Factors; Tumor Cells, Cultured | 2004 |
The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorescence; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins | 2007 |